PT2137217E - Métodos para inibir a ligação da endosialina a ligandos - Google Patents
Métodos para inibir a ligação da endosialina a ligandos Download PDFInfo
- Publication number
- PT2137217E PT2137217E PT87331252T PT08733125T PT2137217E PT 2137217 E PT2137217 E PT 2137217E PT 87331252 T PT87331252 T PT 87331252T PT 08733125 T PT08733125 T PT 08733125T PT 2137217 E PT2137217 E PT 2137217E
- Authority
- PT
- Portugal
- Prior art keywords
- endosialin
- ligands
- inhibiting
- binding
- methods
- Prior art date
Links
- 102100038083 Endosialin Human genes 0.000 title 1
- 101710144543 Endosialin Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91036207P | 2007-04-05 | 2007-04-05 | |
| US98002607P | 2007-10-15 | 2007-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2137217E true PT2137217E (pt) | 2014-03-20 |
Family
ID=39714208
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87331252T PT2137217E (pt) | 2007-04-05 | 2008-04-04 | Métodos para inibir a ligação da endosialina a ligandos |
| PT131627739T PT2620451T (pt) | 2007-04-05 | 2008-04-04 | Métodos para inibir a ligação da endosialina a ligandos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT131627739T PT2620451T (pt) | 2007-04-05 | 2008-04-04 | Métodos para inibir a ligação da endosialina a ligandos |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US7807382B2 (enExample) |
| EP (2) | EP2620451B1 (enExample) |
| JP (2) | JP5825784B2 (enExample) |
| KR (1) | KR101529334B1 (enExample) |
| CN (1) | CN101918446B (enExample) |
| AU (1) | AU2008237296B2 (enExample) |
| BR (1) | BRPI0809665B8 (enExample) |
| CA (1) | CA2682726C (enExample) |
| CY (2) | CY1115370T1 (enExample) |
| DK (2) | DK2137217T3 (enExample) |
| ES (2) | ES2606906T3 (enExample) |
| HR (2) | HRP20140266T1 (enExample) |
| HU (1) | HUE031269T2 (enExample) |
| LT (1) | LT2620451T (enExample) |
| MX (1) | MX2009010701A (enExample) |
| PL (2) | PL2620451T3 (enExample) |
| PT (2) | PT2137217E (enExample) |
| RS (2) | RS53362B (enExample) |
| SI (2) | SI2137217T1 (enExample) |
| WO (1) | WO2008124570A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607455A1 (en) * | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
| WO2008124570A1 (en) * | 2007-04-05 | 2008-10-16 | Morphotek, Inc. | Methods for inhibiting the binding of endosialin to ligands |
| WO2009126725A1 (en) * | 2008-04-09 | 2009-10-15 | The Regents Of The University Of Michigan | Method of modulating neovascularization |
| US20100260769A1 (en) * | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
| US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
| WO2012050883A1 (en) | 2010-09-29 | 2012-04-19 | Morphotek, Inc. | Engineered human endosialin-expressing rodents |
| JP6285414B2 (ja) | 2012-03-30 | 2018-02-28 | モルフォテック， インコーポレイテッド | Ｔｅｍ−１診断用抗体 |
| US9783610B2 (en) * | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
| US20160015750A1 (en) | 2013-03-09 | 2016-01-21 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| GB201702926D0 (en) * | 2017-02-23 | 2017-04-12 | Univ Birmingham | Modulators |
| IL272246B1 (en) | 2017-07-28 | 2025-09-01 | Applied Therapeutics Inc | Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia |
| CN110531077B (zh) * | 2018-05-25 | 2023-07-07 | 荣昌生物制药(烟台)股份有限公司 | 间皮素免疫组化检测试剂盒 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113966396A (zh) | 2019-05-07 | 2022-01-21 | 迈阿密大学 | 遗传性神经病和相关障碍的治疗和检测 |
| CN111026023A (zh) * | 2020-01-12 | 2020-04-17 | 安徽楚江科技新材料股份有限公司 | 基于s7-400控制系统的铜带轧机PLC组态方法 |
| CN116790744B (zh) * | 2023-06-30 | 2024-04-26 | 浙江大学 | 一种缺血性心脏病晚期纤维化干预靶点及其应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5342757A (en) | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
| DE69432926T2 (de) | 1993-02-05 | 2004-05-13 | Epigen, Inc., Wellesley | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
| DE69535002T2 (de) | 1994-03-08 | 2006-12-07 | Memorial Sloan-Kettering Cancer Center | Rekombinante humanisierte antikörper gegen fb5 |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US6146894A (en) | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US6263223B1 (en) | 1998-09-09 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Method for monitoring arterial oxygen saturation |
| US20040029123A1 (en) | 2000-03-15 | 2004-02-12 | Alexander Olek | Diagnosis of diseases associated with the cell cycle |
| WO2002010217A2 (en) | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Endothelial cell expression patterns |
| CA2434926C (en) | 2001-01-15 | 2014-04-01 | Morphotek, Inc. | Chemical inhibitors of mismatch repair |
| US20040043928A1 (en) | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20040014058A1 (en) | 2001-10-05 | 2004-01-22 | Alsobrook John P. | Novel human proteins, polynucleotides encoding them and methods of using the same |
| JP2006512924A (ja) | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | 脳内皮細胞発現パターン |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| JP4928259B2 (ja) | 2003-03-04 | 2012-05-09 | キリンホールディングス株式会社 | 内皮細胞特異的抗体およびその使用 |
| WO2005086713A2 (en) * | 2004-03-04 | 2005-09-22 | Kirin Brewery Co., Ltd. | Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis |
| WO2006017759A2 (en) | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
| WO2006029045A2 (en) | 2004-09-03 | 2006-03-16 | Kirin Brewery Co., Ltd. | Endothelial cell specific antibodies and uses thereof |
| US20070292354A1 (en) | 2004-09-23 | 2007-12-20 | Guerbet | Contrast Agents Encapsulating Systems for Cest Imaging |
| CA2590583A1 (en) | 2004-12-03 | 2006-06-08 | Morphotek, Inc. | Use of endosialin binding proteins to isolate endosialin positive cells |
| EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| CA2607455A1 (en) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
| US7315372B1 (en) * | 2005-09-29 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Navy | Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions |
| DE102005050933A1 (de) | 2005-10-21 | 2007-04-26 | Justus-Liebig-Universität Giessen | Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen |
| US7908090B2 (en) | 2005-11-30 | 2011-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Signatures for human aging |
| JP2009523709A (ja) | 2005-12-16 | 2009-06-25 | ジェネンテック・インコーポレーテッド | 神経膠腫の診断、予後の予測及び治療の方法 |
| WO2008084331A2 (en) | 2006-06-21 | 2008-07-17 | Hopitaux Universitaires De Geneve | Biomarkers for renal disorders |
| EP2041307A2 (en) | 2006-07-13 | 2009-04-01 | Siemens Healthcare Diagnostics GmbH | Prediction of breast cancer response to taxane-based chemotherapy |
| WO2008009132A1 (en) | 2006-07-21 | 2008-01-24 | The Governors Of The University Of Alberta | Tissue rejection |
| EP2949763A3 (en) | 2006-08-11 | 2016-03-09 | Johns Hopkins University | Consensus coding sequences of human breast cancers |
| US20080300170A1 (en) | 2006-09-01 | 2008-12-04 | Cohava Gelber | Compositions and methods for diagnosis and treatment for type 2 diabetes |
| US20100092476A1 (en) | 2006-11-17 | 2010-04-15 | Hanash Samir M | Pancreatic cancer biomarkers |
| WO2008097908A2 (en) | 2007-02-05 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and prognosing lung cancer |
| WO2008101118A2 (en) | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| WO2008124570A1 (en) | 2007-04-05 | 2008-10-16 | Morphotek, Inc. | Methods for inhibiting the binding of endosialin to ligands |
| EP1986010A1 (en) | 2007-04-05 | 2008-10-29 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and tools for discriminating colorectal adenomas and adenocarcinomas |
| EP2176665B1 (en) | 2007-08-16 | 2016-03-02 | The Royal Institution for the Advancement of Learning / McGill University | Tumor cell-derived microvesicles |
| EP2604704B1 (en) | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| WO2009105549A2 (en) | 2008-02-19 | 2009-08-27 | Oncomethylome Sciences Sa | Detection and prognosis of lung cancer |
| US20110117111A1 (en) | 2008-03-26 | 2011-05-19 | Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| US20100136584A1 (en) | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| US20110256560A1 (en) | 2008-10-20 | 2011-10-20 | University Health Network | Methods and compositions for the detection of ovarian cancer |
| NZ628463A (en) | 2009-01-14 | 2015-12-24 | Us Health | Ratio based biomarkers and methods for use thereof |
| US20100260769A1 (en) | 2009-04-09 | 2010-10-14 | Morphotek, Inc. | Endosialin binding molecules |
-
2008
- 2008-04-04 WO PCT/US2008/059374 patent/WO2008124570A1/en not_active Ceased
- 2008-04-04 RS RS20140299A patent/RS53362B/sr unknown
- 2008-04-04 DK DK08733125.2T patent/DK2137217T3/en active
- 2008-04-04 SI SI200831213T patent/SI2137217T1/sl unknown
- 2008-04-04 PL PL13162773T patent/PL2620451T3/pl unknown
- 2008-04-04 PT PT87331252T patent/PT2137217E/pt unknown
- 2008-04-04 LT LTEP13162773.9T patent/LT2620451T/lt unknown
- 2008-04-04 JP JP2010502317A patent/JP5825784B2/ja active Active
- 2008-04-04 ES ES13162773.9T patent/ES2606906T3/es active Active
- 2008-04-04 EP EP13162773.9A patent/EP2620451B1/en active Active
- 2008-04-04 BR BRPI0809665A patent/BRPI0809665B8/pt active IP Right Grant
- 2008-04-04 HR HRP20140266AT patent/HRP20140266T1/hr unknown
- 2008-04-04 RS RS20161097A patent/RS55447B1/sr unknown
- 2008-04-04 HU HUE13162773A patent/HUE031269T2/en unknown
- 2008-04-04 SI SI200831729A patent/SI2620451T1/sl unknown
- 2008-04-04 PL PL08733125T patent/PL2137217T3/pl unknown
- 2008-04-04 CA CA2682726A patent/CA2682726C/en active Active
- 2008-04-04 ES ES08733125.2T patent/ES2452929T3/es active Active
- 2008-04-04 AU AU2008237296A patent/AU2008237296B2/en not_active Ceased
- 2008-04-04 CN CN200880011474.9A patent/CN101918446B/zh active Active
- 2008-04-04 EP EP08733125.2A patent/EP2137217B1/en active Active
- 2008-04-04 KR KR1020097023061A patent/KR101529334B1/ko active Active
- 2008-04-04 US US12/062,630 patent/US7807382B2/en active Active
- 2008-04-04 DK DK13162773.9T patent/DK2620451T3/da active
- 2008-04-04 MX MX2009010701A patent/MX2009010701A/es active IP Right Grant
- 2008-04-04 PT PT131627739T patent/PT2620451T/pt unknown
-
2010
- 2010-09-01 US US12/873,667 patent/US8895000B2/en active Active
-
2013
- 2013-03-01 JP JP2013041304A patent/JP2013150618A/ja active Pending
-
2014
- 2014-05-23 CY CY20141100365T patent/CY1115370T1/el unknown
- 2014-10-08 US US14/509,353 patent/US9505842B2/en active Active
-
2016
- 2016-10-17 US US15/295,177 patent/US10053509B2/en active Active
- 2016-11-14 CY CY20161101166T patent/CY1118592T1/el unknown
- 2016-12-14 HR HRP20161715TT patent/HRP20161715T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2620451T (lt) | Endosialino prijungimo prie ligandų slopinimo būdai | |
| PL2254579T3 (pl) | Zastosowanie związków wiążących się do ligandów receptora sigma do leczenia bólu neuropatycznego powstającego w konsekwencji chemioterapii | |
| SG10201508789TA (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| ZA201106074B (en) | Pyridazinone compounds | |
| IL213160A0 (en) | Compounds useful for inhibiting chk1 | |
| IL197632A0 (en) | Use of jam-c binding compounds | |
| IL212812A0 (en) | Ligands that bind il-13 | |
| IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
| EP2155759A4 (en) | METHODS FOR THE PREPARATION OF DIORGANOZINC COMPOUNDS | |
| IL213675A0 (en) | Chiral ligands | |
| ZA201102763B (en) | Ligands that have binding specificity for dc-sign | |
| IL212865A0 (en) | Chiral ligands | |
| GB0716714D0 (en) | Ligands | |
| GB0808069D0 (en) | Small molecule inhibition of factor H binding | |
| GB0809888D0 (en) | Small molecule inhibition of factor H binding | |
| PL385227A1 (pl) | Wkład filtra magnetycznego | |
| ZA201100789B (en) | Pyrrolidin-2-ones as hdm2 ligands | |
| GB0809130D0 (en) | Corrosion filters | |
| GB0700502D0 (en) | Methods to add audio descriptions to controls | |
| GB0715202D0 (en) | Improvements to taps | |
| GB0701485D0 (en) | Ligands | |
| GB0700576D0 (en) | Composition for kidney conditions | |
| HK1151243A (en) | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | |
| GB0905293D0 (en) | Agents to prevent binding | |
| GB201000746D0 (en) | Gp 120 binding compounds |